inclusion criteria: 1. informed consent form signed. 2. males and females aged 18-60 years; 3. diagnosis of coronavirus disease caused by sars-cov-2 (covid-19) in a mild or moderate form (without respiratory failure). 4. duration of infection symptoms shall be no more than 6 days before randomization. 5. sars-cov-2 infection should be verified by pcr at the screening. 6. ability to follow the protocol and fulfill all the clinical study procedures. 7. ability and willingness of the subjects and their sexual partners with retained childbearing potential to use reliable contraception methods throughout the study and for 3 months after the treatment completion. 8. willingness not to take alcohol throughout the study.

inclusion criteria: 1. informed consent form signed. 2. males and females aged 18-60 years; 3. diagnosis of coronavirus disease caused by sars-cov-2 (covid-19) in a mild or moderate form (without respiratory failure). 4. duration of infection symptoms shall be no more than 6 days before randomization. 5. sars-cov-2 infection should be verified by pcr at the screening. 6. ability to follow the protocol and fulfill all the clinical study procedures. 7. ability and willingness of the subjects and their sexual partners with retained childbearing potential to use reliable contraception methods throughout the study and for 3 months after the treatment completion. 8. willingness not to take alcohol throughout the study.

inclusion criteria: informed consent form signed. males and females aged 18-60 years; diagnosis of coronavirus disease caused by sars-cov-2 (covid-19) in a mild or moderate form (without respiratory failure). duration of infection symptoms shall be no more than 6 days before randomization. sars-cov-2 infection should be verified by pcr at the screening. ability to follow the protocol and fulfill all the clinical study procedures. ability and willingness of the subjects and their sexual partners with retained childbearing potential to use reliable contraception methods throughout the study and for 3 months after the treatment completion. willingness not to take alcohol throughout the study.

inclusion criteria: informed consent form signed. males and females aged 18-60 years; diagnosis of coronavirus disease caused by sars-cov-2 (covid-19) in a mild or moderate form (without respiratory failure). duration of infection symptoms shall be no more than 6 days before randomization. sars-cov-2 infection should be verified by pcr at the screening. ability to follow the protocol and fulfill all the clinical study procedures. ability and willingness of the subjects and their sexual partners with retained childbearing potential to use reliable contraception methods throughout the study and for 3 months after the treatment completion. willingness not to take alcohol throughout the study.

inclusion criteria: 1. informed consent form signed. 2. males and females aged 18-60 years; 3. diagnosis of coronavirus disease caused by sars-cov-2 (covid-19) in a mild or moderate form (without respiratory failure). 4. duration of infection symptoms shall be no more than 6 days before randomization. 5. sars-cov-2 infection should be verified by pcr at the screening. 6. ability to follow the protocol and fulfill all the clinical study procedures. 7. ability and willingness of the subjects and their sexual partners with retained childbearing potential to use reliable contraception methods throughout the study and for 3 months after the treatment completion. 8. willingness not to take alcohol throughout the study.

inclusion criteria: 1. informed consent form signed. 2. males and females aged 18-60 years; 3. diagnosis of coronavirus disease caused by sars-cov-2 (covid-19) in a mild or moderate form (without respiratory failure). 4. duration of infection symptoms shall be no more than 6 days before randomization. 5. sars-cov-2 infection should be verified by pcr at the screening. 6. ability to follow the protocol and fulfill all the clinical study procedures. 7. ability and willingness of the subjects and their sexual partners with retained childbearing potential to use reliable contraception methods throughout the study and for 3 months after the treatment completion. 8. willingness not to take alcohol throughout the study.